Last reviewed · How we verify

ropivicaine 0.2% — Competitive Intelligence Brief

ropivicaine 0.2% (ropivicaine 0.2%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic (amide). Area: Anesthesia.

marketed Local anesthetic (amide) Voltage-gated sodium channels Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

ropivicaine 0.2% (ropivicaine 0.2%) — University of Alabama at Birmingham. Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ropivicaine 0.2% TARGET ropivicaine 0.2% University of Alabama at Birmingham marketed Local anesthetic (amide) Voltage-gated sodium channels
Lidocaine solution ("A") Lidocaine solution ("A") Hospital Universitari de Bellvitge marketed Local anesthetic Voltage-gated sodium channels
Propofol/Lidocaine Propofol/Lidocaine NYU Langone Health marketed Intravenous anesthetic combination GABA-A receptor (propofol); voltage-gated sodium channels (lidocaine)
lamotrigine (generic Teva) lamotrigine (generic Teva) University of Maryland, Baltimore marketed Anticonvulsant / Mood stabilizer Voltage-gated sodium channels; glutamate release inhibition
Lidocaine (drug) Lidocaine (drug) Daniel A Tonetti, MD marketed Local anesthetic Voltage-gated sodium channels
Bupivacaine Liposomes(BL) Bupivacaine Liposomes(BL) Huazhong University of Science and Technology marketed Local anesthetic (liposomal formulation) Voltage-gated sodium channels
Lidocaine gel 2% Lidocaine gel 2% Atlantic Health System marketed Local anesthetic Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic (amide) class)

  1. Poznan University of Medical Sciences · 4 drugs in this class
  2. Nantes University Hospital · 3 drugs in this class
  3. Bozyaka Training and Research Hospital · 2 drugs in this class
  4. ASST Gaetano Pini-CTO · 2 drugs in this class
  5. Centre Hospitalier Universitaire de Nīmes · 1 drug in this class
  6. Chiang Mai University · 1 drug in this class
  7. Beijing Tiantan Hospital · 1 drug in this class
  8. Complejo Hospitalario Universitario de Granada · 1 drug in this class
  9. Ciusss de L'Est de l'Île de Montréal · 1 drug in this class
  10. China Medical University, China · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ropivicaine 0.2% — Competitive Intelligence Brief. https://druglandscape.com/ci/ropivicaine-0-2. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: